| Literature DB >> 12833567 |
Mustapha Bourhim1, Luc Darnige, Cécile Legallais, Josiane Arvieux, Ramiro Cevallos, Claire Pouplard, Mookambeswaran A Vijayalakshmi.
Abstract
The antiphospholipid syndrome is defined by the presence of antiphospholipid antibodies associated with arterial and/or venous thrombosis, and recurrent abortion accompanied often by thrombocytopenia. These antibodies are heterogeneous and react against phospholipid-binding proteins such as beta2-glycoprotein I (beta2GPI) and prothrombin. The recognition of anti-beta2-glycoprotein I (anti-beta2GPI) by platelet factor 4-heparin complex (PF4-Hc) has been previously evoked and partially confirmed by the present inhibition studies. Further, the anti-beta2-glycoprotein I antibodies were purified from a patient with primary antiphospholipid syndrome using Affi-gel-10-beta2GPI immunoaffinity chromatography. The purified anti-beta2GPI IgM as well as patient serum equally recognized PF4-Hc in ELISA mode. In order to substantiate this data and to better understand we studied an animal model using mouse active immunization with the purified human anti-beta2GPI. The mice showed a significant decrease in their platelet count. In addition the ELISA responses of the immunized mice sera were positive against both beta2GPI and PF4-Hc, substantiating the double recognition. Despite many previous reported animal model studies, this is the first time we have shown the specific recognition of anti-beta2GPI antibodies by PF4-Hc, the results in the induced mice correlating the data observed with some patients. Copyright 2003 John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12833567 DOI: 10.1002/jmr.619
Source DB: PubMed Journal: J Mol Recognit ISSN: 0952-3499 Impact factor: 2.137